- Home
- ACHV
as 05-20-2024 9:34am EST
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
| Founded: | N/A | Country: | Canada |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 150.4M | IPO Year: | N/A |
| Target Price: | $14.00 | AVG Volume (30 days): | 119.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.03 - $8.37 | Next Earning Date: | 05-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Achieve Life Sciences Inc. (ACHV)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Stewart Richard Alistair | ACHV | Executive Chairman | Mar 4 '24 | Buy | $4.59 | 10,000 | $45,850.00 | 38,501 | SEC Form 4 |
| Bencich John | ACHV | CEO | Mar 4 '24 | Buy | $4.59 | 10,000 | $45,850.00 | 76,724 | SEC Form 4 |
Latest Achieve Life Sciences Inc. News
ACHV Breaking Stock News: Dive into ACHV Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
MT Newswires
7 days ago
Oppenheimer Adjusts Achieve Life Sciences Price Target to $11 From $18, Maintains Outperform Rating
Zacks Small Cap Research
7 days ago
ACHV: First Quarter Results
GuruFocus.com
10 days ago
Achieve Life Sciences Inc (ACHV) Reports Q1 2024 Financial Results
Insider Monkey
10 days ago
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q1 2024 Earnings Call Transcript
GlobeNewswire
11 days ago
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
GlobeNewswire
14 days ago
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
ACCESSWIRE
21 days ago